AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18997913 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + insertion of doxycycline gel (SRP+DH)
Number of subjects: 30
Study 18997913 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + insertion of chlorhexidine gel (SRP+CHX)
Number of subjects: 30
Study 18997913 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study 17116095 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC (Headache and Pain Clinic)
Number of subjects: 181
Study 17116095 — intervention group
Group type: COMPARATOR
Intervention: GP patients
Number of subjects: 181
Study 17116095 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC patients
Number of subjects: 181
Study 17116095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 181
Study 12667121 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone (INR of 2.8 IU)
Number of subjects: 3620
Study 12667121 — intervention group
Group type: COMPARATOR
Intervention: Combination of aspirin (75 mg/day) and warfarin (INR of 2.2 IU)
Number of subjects: 3620
Study 12667121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (160 mg/day)
Number of subjects: 3620
Study 12667121 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin alone
Number of subjects: 3620
Study 12667121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and warfarin
Number of subjects: 3620
Study 12667121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 3620
Study 10941621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (300 mg) with kinnow juice (300 ml)
Number of subjects: 10
Study 10941621 — intervention group
Group type: COMPARATOR
Intervention: Sustained release theophylline (300 mg) with water (300 ml)
Number of subjects: 10
Study 9322135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic withdrawal
Number of subjects: 36
Study 7886617 — intervention group
Group type: EXPERIMENTAL
Intervention: High transfusion rates with subcutaneous desferrioxamine injections (Group A)
Number of subjects: 18
Study 7886617 — intervention group
Group type: EXPERIMENTAL
Intervention: High transfusion without desferrioxamine (Group B)
Number of subjects: 18
Study 7886617 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining pretransfusion Hb levels between 6-7 g/dl (Group C)
Number of subjects: 18
Study 3522813 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (100 mg daily for 4 weeks)
Number of subjects: 31
Study 3522813 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 31410338 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (10 gm two hours before radiotherapy, five days a week during the seven-week course)
Number of subjects: 60
Study 31410338 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemo-radiotherapy with oral glutamine
Number of subjects: 60
Study 31410338 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine
Number of subjects: 60
Study 28380627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening intervention (Fe en Acción)
Number of subjects: 436
Study 28380627 — intervention group
Group type: COMPARATOR
Intervention: Physical activity intervention (control)
Number of subjects: 436
Study 26324049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7213
Study 26324049 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin
Number of subjects: 7213
Study 26324049 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI Bivalirudin infusion
Number of subjects: 7213
Study 26324049 — intervention group
Group type: COMPARATOR
Intervention: No post-PCI infusion
Number of subjects: 7213
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary inulin
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis + inulin
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis + Tetraselmis chuii
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis + Phaeodactylum tricornutum
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin + Bacillus subtilis
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin + Phaeodactylum tricornutum
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental diets containing Bacillus subtilis
Number of subjects: 0
Study 23318995 — intervention group
Group type: EXPERIMENTAL
Intervention: All assayed diets
Number of subjects: 0
Study 23318995 — intervention group
Group type: COMPARATOR
Intervention: Control diet (not specified)
Number of subjects: 0
Study 21737072 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen-thawed embryo transfer (FET)
Number of subjects: 103
Study 21737072 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer (ET)
Number of subjects: 103
Study 19659622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 110
Study 16773434 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 1176
Study 16773434 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 1176
Study 15309879 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Number of subjects: 20
Study 15309879 — intervention group
Group type: COMPARATOR
Intervention: No eradication of H. pylori
Number of subjects: 20
Study 11116284 — intervention group
Group type: EXPERIMENTAL
Intervention: LJP-394, 100 mg intravenously weekly
Number of subjects: 0
Study 9150290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 20
Study 9150290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8121962 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 0
Study 8121962 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 3501751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 0
Study 3501751 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 100mg single dose
Number of subjects: 0
Study 3501751 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 0
Study 3501751 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 0
Study 30354782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular Vascular Closure Device (VCD)
Number of subjects: 1395
Study 30354782 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravascular Vascular Closure Device (VCD)
Number of subjects: 1395
Study 30354782 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 1395
Study 26617051 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 437
Study 25458454 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 coloading (GroupV)
Number of subjects: 120
Study 25458454 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution coloading (GroupC)
Number of subjects: 120
Study 22374637 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cognitive function measured by Digit Symbol Substitution Test (DSST)
Number of subjects: 2956
Study 22374637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline over 20 months
Number of subjects: 2956
Study 22374637 — intervention group
Group type: COMPARATOR
Intervention: Randomization to intensive glycemic strategy
Number of subjects: 2956
Study 22374637 — intervention group
Group type: COMPARATOR
Intervention: Randomization to standard glycemic strategy
Number of subjects: 2956
Study 20462055 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shegan Mahuang Decoction (SGMH), one dose per day for 4 weeks
Number of subjects: 154
Study 20462055 — intervention group
Group type: COMPARATOR
Intervention: Montelukast, once a day for 4 weeks (4 mg for ages 2-5, 5 mg for ages 6-14)
Number of subjects: 154
Study 20462055 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group for cytokine levels)
Number of subjects: 154
Study 17681803 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Number of subjects: 275
Study 17681803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 15557131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 46
Study 12426013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IV
Number of subjects: 324
Study 12426013 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 50 mg IV
Number of subjects: 324
Study 10598706 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the globus pallidus internus (GPi)
Number of subjects: 10
Study 10598706 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 10
Study 10598706 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the globus pallidus internus (GPi) with L-dopa
Number of subjects: 10
Study 10598706 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) with L-dopa
Number of subjects: 10
Study 10598706 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at either site
Number of subjects: 10
Study 8614043 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-cm H2O PEEP
Number of subjects: 44
Study 8614043 — intervention group
Group type: COMPARATOR
Intervention: 0-cm H2O PEEP (ZEEP)
Number of subjects: 44
Study 1936074 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine tablets (treatment A)
Number of subjects: 18
Study 1936074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxonidine solution (treatment B)
Number of subjects: 18
Study 6152884 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of beta-receptor blockade
Number of subjects: 43
Study 6152884 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of beta-receptor blockade
Number of subjects: 43
Study 30887470 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Number of subjects: 0
Study 30887470 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) chemotherapy
Number of subjects: 0
Study 29695902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 28.8 μg
Number of subjects: 66
Study 29695902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 14.4 μg
Number of subjects: 66
Study 29695902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 7.2 μg
Number of subjects: 66
Study 29695902 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 66
Study 29695902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI (all doses)
Number of subjects: 66
Study 25943172 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bevacizumab 5 mg/mL
Number of subjects: 90
Study 25943172 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bevacizumab 10 mg/mL
Number of subjects: 90
Study 25943172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25007694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 378
Study 25007694 — intervention group
Group type: COMPARATOR
Intervention: Simple head extension
Number of subjects: 378
Study 22344744 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 14
Study 22344744 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone (20 mg)
Number of subjects: 14
Study 22344744 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10 mg)
Number of subjects: 14
Study 22344744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19865833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (4 sessions)
Number of subjects: 174
Study 19865833 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-experiential group therapy (4 sessions)
Number of subjects: 174
Study 19865833 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control group, n = 91)
Number of subjects: 174
Study 16765100 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (4 sessions at 3-month intervals for 1 year)
Number of subjects: 190
Study 16765100 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard medical care)
Number of subjects: 190
Study 16765100 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 190
Study 16765100 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 190
Study 15517339 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-day spaceflight
Number of subjects: 4
Study 15517339 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 ambulatory men)
Number of subjects: 4
Study 12209483 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information (4 minutes, 20 seconds duration)
Number of subjects: 112
Study 12209483 — intervention group
Group type: COMPARATOR
Intervention: No video information
Number of subjects: 112
Study 10590432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS) using transcervical biopsy forceps
Number of subjects: 1313
Study 10590432 — intervention group
Group type: COMPARATOR
Intervention: Mid-trimester amniocentesis
Number of subjects: 1313
Study 8624224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.76% sodium monofluorophosphate (MFP)
Number of subjects: 0
Study 8624224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.247% sodium fluoride (NaF)
Number of subjects: 0
Study 8624224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.247% sodium fluoride (NaF) plus 1.3% pyrophosphate and 1.5% polyvinylmethyl ether/maleic acid (PVM/MA) copolymer (NaF/PPi)
Number of subjects: 0
Study 8624224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-fluoride dentifrice)
Number of subjects: 0
Study 1850339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate (Florinef) for 3 weeks
Number of subjects: 15
Study 1850339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (i.v. administration)
Number of subjects: 15
Study 1850339 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 15
Study 6991446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg digoxin
Number of subjects: 18
Study 6991446 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg digoxin over four days
Number of subjects: 18
Study 6991446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31241381 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported xerostomia assessment using EORTC QLQ-H&N35 questionnaire
Number of subjects: 109
Study 31241381 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-rated xerostomia assessment using DAHANCA toxicity scale
Number of subjects: 109
Study 31241381 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-variable analysis including doses to the oral cavity, tobacco status, and use of xerogenic medication
Number of subjects: 109
Study 31241381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-volume histogram (DVH) analysis and principal component analysis (PCA)
Number of subjects: 109
Study 28399129 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care anxiety and depression screening prompted by an automated electronic template comprising five questions (including a two-item Patient Health Questionnaire-2 for depression and a two-item Generalized Anxiety Disorder-2 questionnaire for anxiety).
Number of subjects: 704
Study 28399129 — intervention group
Group type: COMPARATOR
Intervention: Control group prompted GPs to ask only the pain intensity question.
Number of subjects: 704
Study 24989855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg administered intra-operatively, and at 4 and 8 weeks after surgery
Number of subjects: 40
Study 24989855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 40
Study 24989855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVB)
Number of subjects: 40
Study 22882281 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (supratherapeutic concentrations)
Number of subjects: 0
Study 22882281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22882281 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 0
Study 21330581 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing region (rebates, messages, and promotion)
Number of subjects: 391
Study 21330581 — intervention group
Group type: COMPARATOR
Intervention: Control region (no incentives)
Number of subjects: 391
Study 21330581 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing region
Number of subjects: 391
Study 19675392 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscular relaxation (PMR) training plus exercise training and lifestyle education (relaxation group; n=55)
Number of subjects: 110
Study 19675392 — intervention group
Group type: COMPARATOR
Intervention: Usual care (exercise training and lifestyle education; control group; n=55)
Number of subjects: 110
Study 17761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying patients' smoking status
Number of subjects: 0
Study 17761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about smoking
Number of subjects: 0
Study 17761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation medication use
Number of subjects: 0
Study 17761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for smoking
Number of subjects: 0
Study 15475437 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort Turbuhaler) 800 microg twice daily inhalation for 6 months
Number of subjects: 112
Study 15475437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 15973519 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln‐PN (0.5 g/kg per day; n=15)
Number of subjects: 29
Study 15973519 — intervention group
Group type: COMPARATOR
Intervention: Control‐PN (standard Gln‐free PN; n=14)
Number of subjects: 29
Study 15973519 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln‐PN
Number of subjects: 29
Study 10442372 — intervention group
Group type: COMPARATOR
Intervention: Oral tamoxifen 20 mg/day for 2 years (group A)
Number of subjects: 444
Study 10442372 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UFT 400 mg/day plus tamoxifen 20 mg/day (group B)
Number of subjects: 444
Study 8755848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients before surgery
Number of subjects: 28
Study 8755848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients after pharmacological treatment
Number of subjects: 28
Study 8755848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients after excision of the tumor
Number of subjects: 28
Study 8755848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma patients before any treatment
Number of subjects: 28
Study 8755848 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 healthy volunteers)
Number of subjects: 28
Study 1914554 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine delivery system (TTS-1, 0.1 mg/day)
Number of subjects: 6
Study 1914554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6351231 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (50 micrograms/puff) one puff per nostril X 4 (daily dose 400 micrograms)
Number of subjects: 70
Study 6351231 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol two puffs per nostril X 2 (daily dose 400 micrograms)
Number of subjects: 70
Study 6351231 — intervention group
Group type: COMPARATOR
Intervention: Placebo one puff per nostril X 4
Number of subjects: 70
Study 6351231 — intervention group
Group type: COMPARATOR
Intervention: Placebo two puffs per nostril X 2
Number of subjects: 70
Study 6351231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active drugs
Number of subjects: 70
Study 6351231 — intervention group
Group type: EXPERIMENTAL
Intervention: NPEF and use of antihistamine tablets
Number of subjects: 70
Study 29776873 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 80
Study 29776873 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 80
Study 29776873 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology + PMR
Number of subjects: 80
Study 29776873 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29326407 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Program for Patients Who Underwent Percutaneous Coronary Intervention (SP-PCI)
Number of subjects: 48
Study 29326407 — intervention group
Group type: COMPARATOR
Intervention: Usual care from primary health care providers and brief health education
Number of subjects: 48
Study 26606004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 39
Study 26606004 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 39
Study 24417602 — intervention group
Group type: EXPERIMENTAL
Intervention: Online positive psychology intervention (OPPI) cultivating optimism
Number of subjects: 466
Study 24417602 — intervention group
Group type: COMPARATOR
Intervention: Control condition writing about daily activities
Number of subjects: 466
Study 22958476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) (Flebogamma®, 2 g/kg)
Number of subjects: 20
Study 22958476 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous therapy)
Number of subjects: 20
Study 19900238 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific Expert Patient Programme (EPP) (n = 162)
Number of subjects: 317